FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Wainberg

Research Profile

Living Beings

HIV-1

Chemicals & Drugs

Disorders

Physiology

Concepts & Ideas

Molecular Sequence Data

Anatomy

Co-author Network

Publications

TOP 3
Ravindra K Gupta; Jan Albert; Francoise Brun-Vezinet; Jose M Gatell; Anders Sönnerborg; Mark A Wainberg; Jean B Nachega
Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs.
Ying-Shan Han; Thibault Mesplède; Jian-Xin Pu; Peter K Quashie; Han-Dong Sun; Olivier Delelis; Eric Deprez; Wei-Lie Xiao; Hongtao Xu; Mark A Wainberg
Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.
Matthew S Parsons; Danielle Rouleau; Jean-Pierre Routy; Cécile L Tremblay; Mark A Wainberg; Marcel D Zannou; Robert J Center; Michael D Grant; Stephen J Kent; Roger Leblanc; Nicole F Bernard
Short Communication: Antibody Responses to Human Immunodeficiency Virus Envelope from Infections with Multiple Subtypes Utilize the 1F7-Idiotypic Repertoire.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Wainberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ravindra K Gupta; Jan Albert; Francoise Brun-Vezinet; Jose M Gatell; Anders Sönnerborg; Mark A Wainberg; Jean B Nachega
Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs.
The Journal of infectious diseases 2013;207 Suppl 2():S101-6.
2013: Ying-Shan Han; Thibault Mesplède; Jian-Xin Pu; Peter K Quashie; Han-Dong Sun; Olivier Delelis; Eric Deprez; Wei-Lie Xiao; Hongtao Xu; Mark A Wainberg
Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.
Antiviral research 2013;98(3):441-8.
2013: Matthew S Parsons; Danielle Rouleau; Jean-Pierre Routy; Cécile L Tremblay; Mark A Wainberg; Marcel D Zannou; Robert J Center; Michael D Grant; Stephen J Kent; Roger Leblanc; Nicole F Bernard
Short Communication: Antibody Responses to Human Immunodeficiency Virus Envelope from Infections with Multiple Subtypes Utilize the 1F7-Idiotypic Repertoire.
AIDS research and human retroviruses 2013;29(5):778-83.
2013: Gerasimos J Zaharatos; Mark A Wainberg
Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication.
Annals of medicine 2013;45(3):236-41.
2013: Eugene L Asahchop; Bluma G Brenner; Ilinca R Ibanescu; Daniela Moisi; Maureen Oliveira; Mark A Wainberg; Hongtao Xu; Cecile Tremblay
Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
AIDS (London, England) 2013;27(6):879-87.
2013: Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Evolution of HIV integrase resistance mutations.
Current opinion in infectious diseases 2013;26(1):43-9.
2013: Peter K Quashie; Thibault Mesplède; Mark A Wainberg
HIV Drug Resistance and the Advent of Integrase Inhibitors.
Current infectious disease reports 2013;15(1):85-100.
2013: Shirin Heidari; Susan Kippax; Papa Salif Sow; Mark A Wainberg
Women hold up half the sky - and half the burden of the HIV epidemic.
Journal of the International AIDS Society 2013;16():18608.
2013: Thibault Mesplède; Nathan Osman; Christos J Petropoulos; Peter K Quashie; Diane N Singhroy; Yingshan Han; Wei Huang; Yolanda Lie; Mark A Wainberg
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.
Retrovirology 2013;10():22.
2013: Richard Sloan; Mark A Wainberg
Harnessing the therapeutic potential of host antiviral restriction factors that target HIV.
Expert review of anti-infective therapy 2013;11(1):1-4.
2013: Mark A Wainberg
Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.
HIV/AIDS (Auckland, N.Z.) 2013;5():41-9.
2013: Daniel A Donahue; Mark A Wainberg
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.
Retrovirology 2013;10():11.
2013: Eugene L Asahchop; Bluma G Brenner; Jorge L Martinez-Cajas; Daniela Moisi; Maureen Oliveira; Peter K Quashie; Cecile L Tremblay; Mark A Wainberg
In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
The Journal of antimicrobial chemotherapy 2013;68(1):105-12.
2012: Hong-Tao Xu; Eugene L Asahchop; Yingshan Han; Matthew McCallum; Maureen Oliveira; Yudong Quan; Peter K Quashie; Mark A Wainberg
Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.
Journal of virology 2012;86(23):12983-90.
2012: Kamalendra Singh; Mark A Wainberg; Hong-Tao Xu; Bechan Sharma; Atsuko Hachiya; Ariel N Hagedorn; Maxwell D Leslie; Zhe Li; Bruno Marchand; Kayla B Matzek; Eleftherios Michailidis; Pieter R Norden; Michael A Parniak; Devendra K Rai; Emily M Ryan; Stefan G Sarafianos
Biochemical mechanism of HIV-1 resistance to rilpivirine.
The Journal of biological chemistry 2012;287(45):38110-23.
2012: Daniel Lamarre; Mark A Wainberg
Staying ahead of viruses: a never ending task.
Current opinion in virology 2012;2(5):569-71.
2012: Mark A Wainberg; Thibault Mesplède; Peter K Quashie
The development of novel HIV integrase inhibitors and the problem of drug resistance.
Current opinion in virology 2012;2(5):656-62.
2012: Eugene L Asahchop; Richard Sloan; Mark A Wainberg; Cécile L Tremblay
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.
Antimicrobial agents and chemotherapy 2012;56(10):5000-8.
2012: Thibault Mesplède; Peter K Quashie; Mark A Wainberg
Resistance to HIV integrase inhibitors.
Current opinion in HIV and AIDS 2012;7(5):401-8.
2012: Ying-Shan Han; Kevork Mekhssian; Thibault Mesplede; Peter Quashie; Craig Fenwick; Hongtao Xu; Mark A Wainberg
A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence.
Journal of virological methods 2012;184(1-2):34-40.
2012: Hong-Tao Xu; Bluma G Brenner; Yingshan Han; Matthew McCallum; Maureen Oliveira; Yudong Quan; Peter K Quashie; Mark A Wainberg
Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.
Journal of virology 2012;86(16):8422-31.
2012: Susan M Schader; Susan P Colby-Germinario; Ruxandra-Ilinca Ibanescu; Thibault Mespléde; Daniela Moisi; Maureen Oliveira; Peter K Quashie; Mark A Wainberg
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
Antimicrobial agents and chemotherapy 2012;56(8):4257-67.
2012: Victor G Kramer; Maureen Oliveira; Susan M Schader; Diane N Singhroy; Richard Sloan; Randy Tressler; Susan P Colby-Germinario; Daniel A Donahue; Mark A Wainberg
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Antimicrobial agents and chemotherapy 2012;56(8):4154-60.
2012: Veronique Michaud; Jacques Turgeon; Tamara Bar-Magen; Zeruesenay Desta; David Flockhart; Mark A Wainberg
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
Pharmacological reviews 2012;64(3):803-33.
2012: Jorge L Martinez-Cajas; Ella Mendelson; Daniela Moisi; Maureen Oliveira; Mark A Wainberg; Eugene L Asahchop; Florence Doualla-Bell; Zehava Grossman; Irene Lisovsky; Bluma G Brenner
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
The Journal of antimicrobial chemotherapy 2012;67(4):988-94.
2012: Daniel A Donahue; Björn D Kuhl; Richard Sloan; Mark A Wainberg
The viral protein Tat can inhibit the establishment of HIV-1 latency.
Journal of virology 2012;86(6):3253-63.
2012: Peter K Quashie; Diane N Singhroy; Mark Richard Underwood; Tamio Fujiwara; Ying-Shan Han; Thibault Mesplède; Maureen Oliveira; Mark A Wainberg
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Journal of virology 2012;86(5):2696-705.
2012: Susan M Schader; Susan P Colby-Germinario; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Maureen Oliveira; Mark A Wainberg
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.
Antimicrobial agents and chemotherapy 2012;56(2):751-6.
2012: Francois Raffi; Mark A Wainberg
Multiple choices for HIV therapy with integrase strand transfer inhibitors.
Retrovirology 2012;9():110.
2012: Mark A Wainberg; Bluma G Brenner
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.
Molecular biology international 2012;2012():256982.
2012: Peter K Quashie; Richard Sloan; Mark A Wainberg
Novel therapeutic strategies targeting HIV integrase.
BMC medicine 2012;10():34.
2012: SHIRIN HEIDARI; Elly Katabira; Susan Kippax; Richard Marlink; Joan Marsh; Ana Marusic; Julio Montaner; Heidi M Nass; Elizabeth Pollitzer; Maria Teresa Ruiz-Cantero; Lorraine Sherr; Papa Salif Sow; Kathleen Squires; Quarraisha Abdool-Karim; Judith D Auerbach; Simone E Buitendijk; Pedro Cahn; Mirjam J Curno; Catherine Hankins; Mark A Wainberg
Gender-sensitive reporting in medical research.
Journal of the International AIDS Society 2012;15(1):11.
2011: Hong-Tao Xu; Eugene L Asahchop; Bluma G Brenner; Maureen Oliveira; Yudong Quan; Peter K Quashie; Mark A Wainberg
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.
Journal of virology 2011;85(21):11300-8.
2011: Art F Y Poon; Jean-Pierre Routy; Mark A Wainberg; Bluma Brenner; David J H F Knapp; Rachel A McGovern; Theresa Mo; P Richard Harrigan
Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data.
AIDS (London, England) 2011;25(16):2019-26.
2011: James B Whitney; So-Yon Lim; Mark A Wainberg
Evolutionary mechanisms of retroviral persistence.
AIDS reviews 2011;13(4):234-9.
2011: Bluma G Brenner; Hugues Charest; Isabelle Hardy; James Koopman; Daniela Moisi; Michel Roger; David Stephens; Reuven Turgel; Mark A Wainberg; Jonathan Weinberg
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec.
The Journal of infectious diseases 2011;204(7):1115-9.
2011: Mark A Wainberg; Daniela Moisi; Maureen Oliveira; Thomas d'Aquin Toni; Bluma G Brenner
Transmission dynamics of the M184V drug resistance mutation in primary HIV infection.
The Journal of antimicrobial chemotherapy 2011;66(10):2346-9.
2011: Björn D Kuhl; Chen Liang; Richard Sloan; Daniel A Donahue; Mark A Wainberg
Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation.
Virology 2011;417(2):353-61.
2011: Susan M Schader; Susan P Colby-Germinario; Jordana R Schachter; Hongtao Xu; Mark A Wainberg
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
AIDS (London, England) 2011;25(13):1585-94.
2011: Mark A Wainberg; Gerasimos J Zaharatos; Bluma G Brenner
Development of antiretroviral drug resistance.
The New England journal of medicine 2011;365(7):637-46.
2011: Björn D Kuhl; Vicky Cheng; Mark A Wainberg; Chen Liang
Tetherin and its viral antagonists.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2011;6(2):188-201.
2011: Bluma G Brenner; Matthew Lowe; Daniela Moisi; Isabelle Hardy; Simon Gagnon; Hugues Charest; Jean Guy Baril; Mark A Wainberg; Michel Roger
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Journal of medical virology 2011;83(5):751-9.
2011: Mark A Wainberg; Kuan-Teh Jeang
XMRV as a human pathogen?
Cell host & microbe 2011;9(4):260-2.
2011: Richard Sloan; Björn D Kuhl; Daniel A Donahue; André Roland; Tamara Bar-Magen; Mark A Wainberg
Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef.
Journal of virology 2011;85(6):2828-36.
2011: Eugene L Asahchop; Maureen Oliveira; Mark A Wainberg; Bluma G Brenner; Daniela Moisi; Thomas d'Aquin Toni; Cecile L Tremblay
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
Antimicrobial agents and chemotherapy 2011;55(2):600-7.
2011: Mayra Solis; Peyman Nakhaei; Mohammad Jalalirad; Judith Lacoste; Renée Douville; Meztli Arguello; Tiejun Zhao; Michael Laughrea; Mark A Wainberg; John Hiscott
RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I.
Journal of virology 2011;85(3):1224-36.
2011: Mark A Wainberg
AIDS: Drugs that prevent HIV infection.
Nature 2011;469(7330):306-7.
2011: Björn D Kuhl; Chen Liang; Richard Sloan; Vicky Cheng; Daniel A Donahue; John Wilkinson; Mark A Wainberg
The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.
PloS one 2011;6(11):e27660.
2011: Mark A Wainberg; Eric A Cohen
Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence.
Retrovirology 2011;8():59.
2011: Richard Sloan; Mark A Wainberg
The role of unintegrated DNA in HIV infection.
Retrovirology 2011;8():52.
2011: Dimitrios Coutsinos; Cédric F Invernizzi; Jorge L Martinez-Cajas; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.
PloS one 2011;6(5):e20208.
2011: Shirin Heidari; Mirjam J Eckert; Susan Kippax; Quarraisha Abdool Karim; Papa Salif Sow; Mark A Wainberg
Time for gender mainstreaming in editorial policies.
Journal of the International AIDS Society 2011;14():11.
2011: Adan Rios; Jorge Quesada; Dallas Anderson; Allan Goldstein; Theresa Fossum; Susan Colby-Germinario; Mark A Wainberg
Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors.
Virus research 2011;155(1):189-94.
2011: Ariel Roldan; Chen Liang; Mark A Wainberg
Structural changes in the SL5 and SL6 leader sequences of HIV-1 RNA following interactions with the viral mGag protein.
Virus research 2011;155(1):98-105.
2010: Mark A Wainberg; Bluma G Brenner
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.
Viruses 2010;2(11):2493-508.
2010: Hong-Tao Xu; Maureen Oliveira; Yudong Quan; Tamara Bar-Magen; Mark A Wainberg
Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
The Journal of antimicrobial chemotherapy 2010;65(11):2291-9.
2010: Tamara Bar-Magen; Daniel A Donahue; Emily I McDonough; Björn D Kuhl; Verena H Faltenbacher; Hongtao Xu; Veronique Michaud; Richard Sloan; Mark A Wainberg
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
AIDS (London, England) 2010;24(14):2171-9.
2010: Mark A Wainberg; Talia Shuldiner; Karine Dahl; Norbert Gilmore
Reconsidering the lifetime deferral of blood donation by men who have sex with men.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2010;182(12):1321-4.
2010: Tamara Bar-Magen; Richard Sloan; Daniel A Donahue; Björn D Kuhl; Alexandra Zabeida; Hongtao Xu; Maureen Oliveira; Daria J Hazuda; Mark A Wainberg
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Journal of virology 2010;84(18):9210-6.
2010: Eugene L Asahchop; Maureen Oliveira; Bluma G Brenner; Jorge L Martinez-Cajas; Thomas d'Aquin Toni; Michel Ntemgwa; Daniela Moisi; Serge Dandache; Brent Stranix; Cecile L Tremblay; Mark A Wainberg
Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.
Antiviral research 2010;87(3):367-72.
2010: Björn D Kuhl; Richard Sloan; Daniel A Donahue; Tamara Bar-Magen; Chen Liang; Mark A Wainberg
Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation.
AIDS (London, England) 2010;24(12):1970-2.
2010: Irene Lisovsky; Susan M Schader; Jorge-Luis Martinez-Cajas; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
Antimicrobial agents and chemotherapy 2010;54(7):2878-85.
2010: Hong-Tao Xu; Yudong Quan; Susan M Schader; Maureen Oliveira; Tamara Bar-Magen; Mark A Wainberg
The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
Antimicrobial agents and chemotherapy 2010;54(6):2401-8.
2010: Mark A Wainberg; Jan Albert
Can the further clinical development of bevirimat be justified?
AIDS (London, England) 2010;24(5):773-4.
2010: Daniel A Donahue; Richard Sloan; Björn D Kuhl; Tamara Bar-Magen; Susan M Schader; Mark A Wainberg
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.
Antimicrobial agents and chemotherapy 2010;54(3):1047-54.
2010: David O Willer; Yongjun Guan; Mark A Luscher; Bing Li; Rick Pilon; Jocelyn Fournier; Monique Parenteau; Mark A Wainberg; Paul Sandstrom; Kelly S MacDonald
Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.
Journal of virology 2010;84(5):2304-17.
2010: Pedro Cahn; Mark A Wainberg
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
The Journal of antimicrobial chemotherapy 2010;65(2):213-7.
2010: Thomas A Toni; Bluma G Brenner; Eugene L Asahchop; Michel Ntemgwa; Daniela Moisi; Mark A Wainberg
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2010;54(2):907-11.
2010: Anita Rachlis; Stephen D Shafran; Cécile Tremblay; Mark A Wainberg; Marianne Harris; Richard Lalonde; Sharon Walmsley
Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada 2010;21(4):159-72.
2010: Björn D Kuhl; Richard Sloan; Daniel A Donahue; Tamara Bar-Magen; Chen Liang; Mark A Wainberg
Tetherin restricts direct cell-to-cell infection of HIV-1.
Retrovirology 2010;7():115.
2010: Hong-Tao Xu; Yudong Quan; Eugene Asahchop; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.
Retrovirology 2010;7():80.
2010: Guido Van Marle; Deirdre L Church; Kali D Nunweiler; Kris Cannon; Mark A Wainberg; M John Gill
Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection.
Retrovirology 2010;7():74.
2010: Richard Sloan; Daniel A Donahue; Björn D Kuhl; Tamara Bar-Magen; Mark A Wainberg
Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.
Retrovirology 2010;7():44.
2010: Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Bluma G Brenner; Mark A Wainberg
Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.
Antiviral chemistry & chemotherapy 2010;20(3):117-31.
2009: Yudong Quan; Chen Liang; Bluma G Brenner; Mark A Wainberg
Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants.
The Journal of infectious diseases 2009;200(9):1479-83.
2009: Hongtao Xu; Yudong Quan; Bluma G Brenner; Tamara Bar-Magen; Maureen Oliveira; Susan M Schader; Mark A Wainberg
Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
Antimicrobial agents and chemotherapy 2009;53(11):4667-72.
2009: Susan Colby-Germinario; Adan Rios; Jorge Quesada; Dallas Anderson; Allan L Goldstein; Theresa Fossum; Mark A Wainberg
HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase.
Vaccine 2009;27(44):6137-42.
2009: Cédric F Invernizzi; Dimitrios Coutsinos; Maureen Oliveira; Daniela Moisi; Bluma G Brenner; Mark A Wainberg
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C.
The Journal of infectious diseases 2009;200(8):1202-6.
2009: Dan Turner; Eduardo Shahar; Eugene Katchman; Eynat Kedem; Natasha Matus; Michal Katzir; Gamal Hassoun; Shimon Pollack; Rivka Kessner; Mark A Wainberg; Boaz Avidor
Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
Journal of medical virology 2009;81(9):1509-12.
2009: Michel Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Antiretroviral drug resistance in human immunodeficiency virus type 2.
Antimicrobial agents and chemotherapy 2009;53(9):3611-9.
2009: Liwei Rong; Jianyong Zhang; Jennifer Lu; Qinghua Pan; René-Pierre Lorgeoux; Claudette Aloysius; Fei Guo; Shan-Lu Liu; Mark A Wainberg; Chen Liang
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Journal of virology 2009;83(15):7536-46.
2009: Mark A Wainberg; Jorge L Martinez-Cajas
Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease.
Infectious disorders drug targets 2009;9(2):172-90.
2009: Maureen Oliveira; Daniela Moisi; Bonnie Spira; Susan Cox; Bluma G Brenner; Mark A Wainberg
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.
Antimicrobial agents and chemotherapy 2009;53(4):1683-5.
2009: Thomas A Toni; Eugene L Asahchop; Daniela Moisi; Michel Ntemgwa; Maureen Oliveira; Bernard Masquelier; Bluma G Brenner; Mark A Wainberg
Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.
Antimicrobial agents and chemotherapy 2009;53(4):1670-2.
2009: Mark A Wainberg
Criminalizing HIV transmission may be a mistake.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2009;180(6):688.
2009: Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.
Journal of virology 2009;83(4):2029-33.
2009: Michel Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Maureen Oliveira; Eugene L Asahchop; Daniela Moisi; Mark A Wainberg
Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.
Antimicrobial agents and chemotherapy 2009;53(2):708-15.
2009: Anita Rachlis; Jonathan B Angel; Marianne Harris; Stephen D Shafran; Rachel Therrien; Cécile Tremblay; Mark A Wainberg
Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada 2009;20(3):e67-80.
2009: Mark A Wainberg
Two standards of care for HIV: why are Africans being short-changed?
Retrovirology 2009;6():109.
2009: Tamara Bar-Magen; Richard Sloan; Verena H Faltenbacher; Daniel A Donahue; Björn D Kuhl; Maureen Oliveira; Hongtao Xu; Mark A Wainberg
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Retrovirology 2009;6():103.
2009: Florence Doualla-Bell; Tendani Gaolathe; Ava Avalos; Suzanne Cloutier; Ndwapi Ndwapi; Christina Holcroft; Howard Moffat; Diana Dickinson; Max Essex; Mark A Wainberg; Madisa Mine
Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.
Journal of the International AIDS Society 2009;12():25.
2009: Jorge L Martinez-Cajas; Nitika P Pai; Marina B Klein; Mark A Wainberg
Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).
Journal of the International AIDS Society 2009;12():11.
2009: Hong-Tao Xu; Jorge L Martinez-Cajas; Michel Ntemgwa; Dimitrios Coutsinos; Fernando A Frankel; Bluma G Brenner; Mark A Wainberg
Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.
Retrovirology 2009;6():14.
2009: Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Isolation of drug-resistant mutant HIV variants using tissue culture drug selection.
Methods in molecular biology (Clifton, N.J.) 2009;485():427-33.
2008: Serge Dandache; Craig A Coburn; Maureen Oliveira; Timothy J Allison; M Katharine Holloway; Jinzi J Wu; Brent R Stranix; Chandra Panchal; Mark A Wainberg; Joseph P Vacca
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Journal of medical virology 2008;80(12):2053-63.
2008: Bluma G Brenner; Michel Roger; Daniela D Moisi; Maureen Oliveira; Isabelle Hardy; Reuven Turgel; Hugues Charest; Jean-Pierre Routy; Mark A Wainberg
Transmission networks of drug resistance acquired in primary/early stage HIV infection.
AIDS (London, England) 2008;22(18):2509-15.
2008: Jorge L Martinez-Cajas; Cédric F Invernizzi; Michel Ntemgwa; Susan M Schader; Mark A Wainberg
The impact of the journalist-to-journalist program on worldwide HIV awareness.
AIDS (London, England) 2008;22(13):1687-8.
2008: Robert M Grant; Dean Hamer; Thomas Hope; Rowena Johnston; Joep Lange; Michael M Lederman; Judy Lieberman; Christopher J Miller; John P Moore; Donald E Mosier; Douglas D Richman; Robert T Schooley; Marty S Springer; Ronald S Veazey; Mark A Wainberg
Whither or wither microbicides?
Science (New York, N.Y.) 2008;321(5888):532-4.
2008: David P Wilson; Paul M Coplan; Mark A Wainberg; Sally M Blower
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(28):9835-40.
2008: Michel Ntemgwa; M John Gill; Bluma G Brenner; Daniela Moisi; Mark A Wainberg
Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection.
AIDS research and human retroviruses 2008;24(7):995-1002.
2008: Michel Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Jean-Pierre Routy; Daniela Moisi; Maureen Oliveira; Mark A Wainberg
Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada.
AIDS research and human retroviruses 2008;24(4):655-9.
2008: Mark A Wainberg
HIV transmission should be decriminalized: HIV prevention programs depend on it.
Retrovirology 2008;5():108.
2008: Jorge L Martinez-Cajas; Cédric F Invernizzi; Michel Ntemgwa; Susan M Schader; Mark A Wainberg
Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries.
Journal of the International AIDS Society 2008;11():2.
2008: Mark A Wainberg; Elly Katabira; SHIRIN HEIDARI
Journal of the International AIDS Society: an important step forward.
Journal of the International AIDS Society 2008;11():1.
2008: Mark A Wainberg; Kuan-Teh Jeang
25 years of HIV-1 research - progress and perspectives.
BMC medicine 2008;6():31.
2008: Yudong Quan; Bluma G Brenner; André Dascal; Mark A Wainberg
Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report.
Retrovirology 2008;5():43.
2008: Jorge L Martinez-Cajas; Mark A Wainberg
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.
Drugs 2008;68(1):43-72.
2007: Jorge L Martinez-Cajas; Mark A Wainberg
Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
Antiviral research 2007;76(3):203-21.
2007: Michel Ntemgwa; Mark A Wainberg; Maureen Oliveira; Daniela Moisi; Richard Lalonde; Valeria Micheli; Bluma G Brenner
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Antimicrobial agents and chemotherapy 2007;51(11):3861-9.
2007: Serge Dandache; Guy Sévigny; Jocelyn Yelle; Brent R Stranix; Neil Parkin; Jonathan M Schapiro; Mark A Wainberg; Jinzi J Wu
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2007;51(11):4036-43.
2007: Mark A Wainberg; Bonaventura Clotet
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review.
AIDS patient care and STDs 2007;21(9):609-20.
2007: Cédric F Invernizzi; Baode Xie; Fernando A Frankel; Matthew Feldhammer; Bibhuti Roy; Stéphane Richard; Mark A Wainberg
Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function.
AIDS (London, England) 2007;21(7):795-805.
2007: Bluma G Brenner; Michel Roger; Jean-Pierre Routy; Daniela Moisi; Michel Ntemgwa; Claudine Matte; Jean-Guy Baril; Rejéan Thomas; Danielle Rouleau; Julie Bruneau; Richard LeBlanc; Mario Legault; Cécile L Tremblay; Hugues Charest; Mark A Wainberg
High rates of forward transmission events after acute/early HIV-1 infection.
The Journal of infectious diseases 2007;195(7):951-9.
2007: Baode Xie; Cédric F Invernizzi; Stéphane Richard; Mark A Wainberg
Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region.
Journal of virology 2007;81(8):4226-34.
2007: Fernando A Frankel; Cédric F Invernizzi; Maureen Oliveira; Mark A Wainberg
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations.
AIDS (London, England) 2007;21(6):665-75.
2007: Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Antimicrobial agents and chemotherapy 2007;51(2):604-10.
2007: Helene Gayle; Mark A Wainberg
The 16th International Conference on AIDS: Will It Leave a Legacy?
Journal of the International AIDS Society 2007;9(2):15.
2007: Helene Gayle; Mark A Wainberg
The 16th International Conference on AIDS: will it leave a legacy?
MedGenMed : Medscape general medicine 2007;9(2):15.
2007: James B Whitney; Mark A Wainberg
Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome.
Retrovirology 2007;4():44.
2007: Fernando A Frankel; Dimitrios Coutsinos; Hongtao Xu; Mark A Wainberg
Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate.
Antiviral chemistry & chemotherapy 2007;18(2):93-101.
2007: Mark A Wainberg; Pedro Cahn; Richard C Bethell; James Sawyer; Susan Cox
Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.
Antiviral chemistry & chemotherapy 2007;18(2):61-70.
2007: Helene Gayle; Mark A Wainberg
Impact of the 16th International Conference on AIDS: can these conferences lead to policy change?
Retrovirology 2007;4():13.
2007: Anne Gatignol; Jean Dubuisson; Mark A Wainberg; Eric A Cohen; Jean-Luc Darlix
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu.
Retrovirology 2007;4():8.
2006: Florence Doualla-Bell; Ava Avalos; Bluma Brenner; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Maureen Oliveira; Daniela Moisi; Ndwapi Ndwapi; Howard Moffat; Max Essex; Mark A Wainberg
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.
Antimicrobial agents and chemotherapy 2006;50(12):4182-5.
2006: Mark A Wainberg
The need to promote public health in the field of illicit drug use.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006;175(11):1395.
2006: Inge Derdelinckx; Mark A Wainberg; Joep M A Lange; Andrew Hill; Yasmin Halima; Charles A B Boucher
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.
PLoS medicine 2006;3(11):e454.
2006: Robert M Grant; Mark A Wainberg
Chemoprophylaxis of HIV infection: moving forward with caution.
The Journal of infectious diseases 2006;194(7):874-6.
2006: Jorge Martinez; Paul Coplan; Mark A Wainberg
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
Antiviral research 2006;71(2-3):343-50.
2006: Mayra Solis; Peter Wilkinson; Raphaelle Romieu; Eduardo Hernandez; Mark A Wainberg; John Hiscott
Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells.
Virology 2006;352(1):86-99.
2006: Bluma G Brenner; Maureen Oliveira; Florence Doualla-Bell; Daniela Moisi; Michel Ntemgwa; Fernando A Frankel; Max Essex; Mark A Wainberg
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
AIDS (London, England) 2006;20(9):F9-13.
2006: Florence Doualla-Bell; Ava Avalos; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Ndwapi Ndwapi; Vladimir Novitsky; Bluma Brenner; Maureen Oliveira; Daniela Moisi; Howard Moffat; Ibou Thior; Max Essex; Mark A Wainberg
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Antimicrobial agents and chemotherapy 2006;50(6):2210-3.
2006: Nimâ Machouf; Réjean Thomas; Vinh-Kim Nguyen; Benoit Trottier; Mohamed-Rachid Boulassel; Mark A Wainberg; Jean-Pierre Routy
Effects of drug resistance on viral load in patients failing antiretroviral therapy.
Journal of medical virology 2006;78(5):608-13.
2006: Mark A Wainberg
Twenty-five years of AIDS: where are we now?
MedGenMed : Medscape general medicine 2006;8(4):21.
2006: James B Whitney; Mark A Wainberg
Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239.
Retrovirology 2006;3():96.
2006: Cédric F Invernizzi; Baode Xie; Stéphane Richard; Mark A Wainberg
PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA.
Retrovirology 2006;3():93.
2006: Dan Turner; Mark A Wainberg
HIV transmission and primary drug resistance.
AIDS reviews 2006;8(1):17-23.
2006: Mark A Wainberg
The XVI International Conference on AIDS: the place to be!
Retrovirology 2006;3():9.
2005: Xiaofeng Guo; Bibhuti Roy; Jing Hu; Ariel Roldan; Mark A Wainberg; Chen Liang
The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA.
Virology 2005;343(2):190-200.
2005: Robert M Grant; Susan Buchbinder; Willard Cates; Edith Clarke; Thomas Coates; Myron S Cohen; Martin Delaney; Guiselly Flores; Pedro Goicochea; Gregg Gonsalves; Mark Harrington; Javier R Lama; Kathleen M MacQueen; John P Moore; Leigh Peterson; Jorge Sanchez; Melanie Thompson; Mark A Wainberg
AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
Science (New York, N.Y.) 2005;309(5744):2170-1.
2005: Yan Desfosses; Mayra Solis; Qiang Sun; Nathalie Grandvaux; Carine Van Lint; Arsène Burny; Anne Gatignol; Mark A Wainberg; Rongtuan Lin; John Hiscott
Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
Journal of virology 2005;79(14):9180-91.
2005: Fernando A Frankel; Bruno Marchand; Dan Turner; Matthias Götte; Mark A Wainberg
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy 2005;49(7):2657-64.
2005: Andrew R Zolopa; Laura C Lazzeroni; Alex Rinehart; Françoise Brun Vezinet; François Clavel; Ann Collier; Brian Conway; Roy M Gulick; Mark Holodniy; Carlo-Frederico Perno; Robert W Shafer; Douglas D Richman; Mark A Wainberg; Daniel R Kuritzkes
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(1):92-9.
2005: Mark A Wainberg; Bluma G Brenner; Dan Turner
Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy 2005;49(5):1671-8.
2005: Ariel Roldan; Otis U Warren; Rodney S Russell; Chen Liang; Mark A Wainberg
A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription.
The Journal of biological chemistry 2005;280(17):17488-96.
2005: Mark A Wainberg
Generic HIV drugs--enlightened policy for global health.
The New England journal of medicine 2005;352(8):747-50.
2005: Xiaofeng Guo; Ariel Roldan; Jing Hu; Mark A Wainberg; Chen Liang
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag.
Journal of virology 2005;79(3):1803-12.
2005: Dan Turner; Bluma Brenner; Daniela Moisi; Chen Liang; Mark A Wainberg
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.
Journal of the International AIDS Society 2005;7(1):69.
2005: Dan Turner; Bluma Brenner; Daniela Mosis; Chen Liang; Mark A Wainberg
Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs.
MedGenMed : Medscape general medicine 2005;7(1):69.
2005: Mark A Wainberg; James P C Sawyer; Julio S G Montaner; Robert L Murphy; Daniel R Kuritzkes; Francois Raffi
Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Antiviral therapy 2005;10(1):13-28.
2005: Marie-Chloé Boulanger; Chen Liang; Rodney S Russell; Rongtuan Lin; Mark T Bedford; Mark A Wainberg; Stéphane Richard
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression.
Journal of virology 2005;79(1):124-31.
2004: Dan Turner; Bluma Brenner; Jean-Pierre Routy; Daniela Moisi; Zeev Rosberger; Michel Roger; Mark A Wainberg
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2004;37(5):1627-31.
2004: Jean-Pierre Routy; Nimâ Machouf; Michael D deB Edwardes; Bluma G Brenner; Réjean Thomas; Benoit Trottier; Danielle Rouleau; Cécile L Tremblay; Pierre Côté; Jean-Guy Baril; Robert S Remis; Rafick-Pierre Sékaly; Mark A Wainberg
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal.
AIDS (London, England) 2004;18(17):2305-12.
2004: Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.
Antimicrobial agents and chemotherapy 2004;48(11):4189-94.
2004: Florence Doualla-Bell; Dan Turner; Hugues Loemba; Marco Petrella; Bluma Brenner; Mark A Wainberg
[HIV drug resistance and optimization of antiviral treatment in resource-poor countries].
Médecine sciences : M/S 2004;20(10):882-6.
2004: Ariel Roldan; Rodney S Russell; Bruno Marchand; Matthias Götte; Chen Liang; Mark A Wainberg
In vitro identification and characterization of an early complex linking HIV-1 genomic RNA recognition and Pr55Gag multimerization.
The Journal of biological chemistry 2004;279(38):39886-94.
2004: Dan Turner; Ariel Roldan; Bluma Brenner; Daniela Moisi; Jean-Pierre Routy; Mark A Wainberg
Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects.
Antiviral chemistry & chemotherapy 2004;15(5):255-9.
2004: Mark A Wainberg; Dan Turner
Resistance issues with new nucleoside/nucleotide backbone options.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S36-43.
2004: Bluma Brenner; Jean-Pierre Routy; Yudong Quan; Daniela Moisi; Maureen Oliveira; Dan Turner; Mark A Wainberg
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.
AIDS (London, England) 2004;18(12):1653-60.
2004: Dan Turner; Bluma Brenner; Daniela Moisi; Mervi Detorio; Raymond Cesaire; Takashi Kurimura; Haruyo Mori; Max Essex; Shlomo Maayan; Mark A Wainberg
Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2004;48(8):2993-8.
2004: Florence Doualla-Bell; Simani Gaseitsiwe; Thumbi Ndungú; Musetsanagepe Modukanele; Trevor Peter; Vladimir Novitsky; Ndwapi Ndwapi; Gaolathe Tendani; Ava Avalos; William Wester; Hermann Bussmann; Peter Cardiello; Richard Marlink; Howard Moffat; Ibou Thior; Mark A Wainberg; Max Essex
Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.
Antiviral chemistry & chemotherapy 2004;15(4):189-200.
2004: Mark A Wainberg
HIV-1 subtype distribution and the problem of drug resistance.
AIDS (London, England) 2004;18 Suppl 3():S63-8.
2004: Mark A Wainberg
The emergence of HIV resistance and new antiretrovirals: are we winning?
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004;7(3):163-7.
2004: Dan Turner; Jonathan M Schapiro; Bluma G Brenner; Mark A Wainberg
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Antiviral therapy 2004;9(3):301-14.
2004: Mark A Wainberg; Bluma G Brenner; Eric Daar; Joseph Gertner; Clement Olivier; Susan Kenley
Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2004;48(6):2337-40.
2004: Dan Turner; Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Mark A Wainberg
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
The new microbiologica 2004;27(2 Suppl 1):31-9.
2004: Mark A Wainberg
The impact of the M184V substitution on drug resistance and viral fitness.
Expert review of anti-infective therapy 2004;2(1):147-51.
2004: Mark A Wainberg
Is there any hope for AIDS?
Clinical and investigative medicine. Médecine clinique et experimentale 2004;27(1):51-8.
2004: Chen Liang; Jing Hu; Rodney S Russell; Masanori Kameoka; Mark A Wainberg
Spliced human immunodeficiency virus type 1 RNA is reverse transcribed into cDNA within infected cells.
AIDS research and human retroviruses 2004;20(2):203-11.
2004: Baode Xie; Valerie Calabro; Mark A Wainberg; Alan D Frankel
Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.
Journal of virology 2004;78(3):1456-63.
2004: Mark A Wainberg
eJIAS: Editor's Welcome.
Journal of the International AIDS Society 2004;6(3):58.
2004: Mark A Wainberg; Helene D Gayle; Joep Ma Lange; Craig McClure; Craig Sterritt
eJIAS: The Journal of HIV/AIDS Science and Medicine in the Developing World.
Journal of the International AIDS Society 2004;6(3):56.
2004: Mark A Wainberg
eJIAS: Editor's Welcome.
MedGenMed : Medscape general medicine 2004;6(3):58.
2004: Rodney S Russell; Chen Liang; Mark A Wainberg
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?
Retrovirology 2004;1():23.
2004: Shalom C Spira; Mark A Wainberg
Jewish religious ethics mandate access to antiretroviral drugs in developing countries.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2004;3(1):7-11.
2004: Marco Petrella; Julio Montaner; Gerald Batist; Mark A Wainberg
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs.
Cancer investigation 2004;22(1):149-60.
2004: Dan Turner; Bluma Brenner; Mark A Wainberg
Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.
The Journal of antimicrobial chemotherapy 2004;53(1):53-7.
2003: Joel E Gallant; Peter Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard Haubrich; Marty St Clair; E Randall Lanier; Nicholas S Hellmann; Douglas D Richman
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
Antiviral therapy 2003;8(6):489-506.
2003: Rodney S Russell; Ariel Roldan; Mervi Detorio; Jing Hu; Mark A Wainberg; Chen Liang
Effects of a single amino acid substitution within the p2 region of human immunodeficiency virus type 1 on packaging of spliced viral RNA.
Journal of virology 2003;77(24):12986-95.
2003: Dan Turner; Bluma Brenner; Mark A Wainberg
Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.
Clinical and diagnostic laboratory immunology 2003;10(6):979-81.
2003: Karidia Diallo; Matthias Götte; Mark A Wainberg
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy 2003;47(11):3377-83.
2003: Liwei Rong; Rodney S Russell; Jing Hu; Michael Laughrea; Mark A Wainberg; Chen Liang
Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1.
Virology 2003;314(1):221-8.
2003: Yudong Quan; Bluma G Brenner; Richard Marlink; Max Essex; Takashi Kurimura; Mark A Wainberg
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C.
AIDS research and human retroviruses 2003;19(9):743-53.
2003: Mark A Wainberg
HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S2-7.
2003: Ralph J Germinario; Susan P Colby-Germinario; C Cammalleri; Mark A Wainberg
The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells.
The Journal of endocrinology 2003;178(3):449-56.
2003: Karidia Diallo; Bruno Marchand; Xin Wei; Luciano Cellai; Matthias Götte; Mark A Wainberg
Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.
Journal of virology 2003;77(16):8621-32.
2003: Mike Youle; Mark A Wainberg
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2003;2(3):102-5.
2003: Karidia Diallo; Bluma Brenner; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Matthias Götte; Mark A Wainberg
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
Antimicrobial agents and chemotherapy 2003;47(7):2376-9.
2003: Xin Wei; Chen Liang; Matthias Götte; Mark A Wainberg
Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis.
Virology 2003;311(1):202-12.
2003: Marina B Klein; Nadia Campeol; Richard G Lalonde; Bluma Brenner; Mark A Wainberg
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
AIDS (London, England) 2003;17(7):1001-8.
2003: Mike Youle; Mark A Wainberg
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?
AIDS (London, England) 2003;17(6):937-8.
2003: Xiaofeng Guo; Masanori Kameoka; Xin Wei; Bernard Roques; Matthias Gotte; Chen Liang; Mark A Wainberg
Suppression of an intrinsic strand transfer activity of HIV-1 Tat protein by its second-exon sequences.
Virology 2003;307(1):154-63.
2003: Shalom Spira; Mark A Wainberg; Hugues Loemba; Dan Turner; Bluma G Brenner
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance.
The Journal of antimicrobial chemotherapy 2003;51(2):229-40.
2003: Yudong Quan; Bluma G Brenner; Maureen Oliveira; Mark A Wainberg
Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.
Antimicrobial agents and chemotherapy 2003;47(2):747-54.
2003: Baode Xie; Mark A Wainberg; Alan D Frankel
Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions.
Journal of virology 2003;77(3):1984-91.
2003: Chen Liang; Jing Hu; James B Whitney; Lawrence Kleiman; Mark A Wainberg
A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1.
Journal of virology 2003;77(3):1772-83.
2003: Bluma Brenner; Dan Turner; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Mauricio Carobene; Richard Marlink; Jonathan Schapiro; Michel Roger; Mark A Wainberg
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
AIDS (London, England) 2003;17(1):F1-5.
2003: Rodney S Russell; Jing Hu; Véronique Bériault; Andrew J Mouland; Michael Laughrea; Lawrence Kleiman; Mark A Wainberg; Chen Liang
Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA.
Journal of virology 2003;77(1):84-96.
2002: Xin Wei; Chen Liang; Matthias Götte; Mark A Wainberg
The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.
AIDS (London, England) 2002;16(18):2391-8.
2002: Hogg Robert; Pedro Cahn; Elly Katabira; Joep Lange; N M Samuel; Michael O'Shaughnessy; STEFANO VELLA; Mark A Wainberg; Julio Montaner
Time to act: global apathy towards HIV/AIDS is a crime against humanity.
Lancet 2002;360(9347):1710-1.
2002: Rodney S Russell; Jing Hu; Michael Laughrea; Mark A Wainberg; Chen Liang
Deficient dimerization of human immunodeficiency virus type 1 RNA caused by mutations of the u5 RNA sequences.
Virology 2002;303(1):152-63.
2002: Chen Liang; Jing Hu; Rodney S Russell; Ariel Roldan; Lawrence Kleiman; Mark A Wainberg
Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag.
Journal of virology 2002;76(22):11729-37.
2002: Hugues Loemba; Bluma Brenner; Michael A Parniak; Shlomo Ma'ayan; Bonnie Spira; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Max Essex; Mark A Wainberg
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
Antiviral research 2002;56(2):129-42.
2002: Chen Liang; Jing Hu; Rodney S Russell; Mark A Wainberg
Translation of Pr55(gag) augments packaging of human immunodeficiency virus type 1 RNA in a cis-acting manner.
AIDS research and human retroviruses 2002;18(15):1117-26.
2002: Marco Petrella; Mark A Wainberg
Might the M184V substitution in HIV-1 RT confer clinical benefit?
AIDS reviews 2002;4(4):224-32.
2002: Bluma G Brenner; Dan Turner; Mark A Wainberg
HIV-1 drug resistance: can we overcome?
Expert opinion on biological therapy 2002;2(7):751-61.
2002: James B Whitney; Maureen Oliveira; Mervi Detorio; Yongjun Guan; Mark A Wainberg
The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.
Journal of virology 2002;76(17):8958-62.
2002: N McLellan; Xin Wei; Bruno Marchand; Mark A Wainberg; Matthias Götte
Nonradioactive detection of retroviral-associated RNase H activity in a microplate-based, high-throughput format.
BioTechniques 2002;33(2):424-9.
2002: Gadi Borkow; Horacio Salomon; Mark A Wainberg; Michael A Parniak
Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor.
AIDS research and human retroviruses 2002;18(10):711-4.
2002: Karidia Diallo; Maureen Oliveira; Daniela Moisi; Bluma Brenner; Mark A Wainberg; Matthias Götte
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2002;46(7):2254-6.
2002: Hugues Loemba; Bluma Brenner; Michael A Parniak; Shlomo Ma'ayan; Bonnie Spira; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Mark A Wainberg
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Antimicrobial agents and chemotherapy 2002;46(7):2087-94.
2002: Hugues Loemba; Bluma Brenner; Michael A Parniak; Shlomo Ma'ayan; Bonnie Spira; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Max Essex; Mark A Wainberg
Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana.
Antiviral therapy 2002;7(2):141-8.
2002: Koen K A Van Rompay; Timothy B Matthews; Joanne Higgins; Don R Canfield; Ross P Tarara; Mark A Wainberg; Ray F Schinazi; Niels C Pedersen; Thomas W North
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.
Journal of virology 2002;76(12):6083-92.
2002: Philippe Roof; Maria Ricci; Pierre Genin; Monty A Montano; Max Essex; Mark A Wainberg; Anne Gatignol; John Hiscott
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.
Virology 2002;296(1):77-83.
2002: Ahmad Khorchid; Rabih Halwani; Mark A Wainberg; Lawrence Kleiman
Role of RNA in facilitating Gag/Gag-Pol interaction.
Journal of virology 2002;76(8):4131-7.
2002: Masanori Kameoka; Max Morgan; Marc Binette; Rodney S Russell; Liwei Rong; Xiaofeng Guo; Andrew J Mouland; Lawrence Kleiman; Chen Liang; Mark A Wainberg
The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription.
Journal of virology 2002;76(8):3637-45.
2002: Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.
Journal of virology 2002;76(4):1753-61.
2002: Chen Liang; Mark A Wainberg
The role of Tat in HIV-1 replication: an activator and/or a suppressor?
AIDS reviews 2002;4(1):41-9.
2002: Fabienne Brulé; Roland Marquet; Liwei Rong; Mark A Wainberg; Bernard P Roques; Stuart F J Le Grice; Bernard Ehresmann; Chantal Ehresmann
Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex.
RNA (New York, N.Y.) 2002;8(1):8-15.
2001: Liwei Rong; Chen Liang; M Hsu; Xiaofeng Guo; Bernard P Roques; Mark A Wainberg
HIV-1 nucleocapsid protein and the secondary structure of the binary complex formed between tRNA(Lys.3) and viral RNA template play different roles during initiation of (-) strand DNA reverse transcription.
The Journal of biological chemistry 2001;276(50):47725-32.
2001: Marco Petrella; Bluma Brenner; Hugues Loemba; Mark A Wainberg
HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2001;4(6):339-46.
2001: Yongjun Guan; Karidia Diallo; James B Whitney; C Liang; Mark A Wainberg
An intact U5-leader stem is important for efficient replication of simian immunodeficiency virus.
Journal of virology 2001;75(23):11924-9.
2001: Yongjun Guan; Karidia Diallo; Mervi Detorio; James B Whitney; C Liang; Mark A Wainberg
Partial restoration of replication of simian immunodeficiency virus by point mutations in either the dimerization initiation site (DIS) or Gag region after deletion mutagenesis within the DIS.
Journal of virology 2001;75(23):11920-3.
2001: N Shen; L Jetté; Mark A Wainberg; Michael Laughrea
Role of stem B, loop B, and nucleotides next to the primer binding site and the kissing-loop domain in human immunodeficiency virus type 1 replication and genomic-RNA dimerization.
Journal of virology 2001;75(21):10543-9.
2001: Liwei Rong; Rodney S Russell; Jing Hu; Yongjun Guan; Lawrence Kleiman; Chen Liang; Mark A Wainberg
Hydrophobic amino acids in the human immunodeficiency virus type 1 p2 and nucleocapsid proteins can contribute to the rescue of deleted viral RNA packaging signals.
Journal of virology 2001;75(16):7230-43.
2001: Brian Conway; Mark A Wainberg; D Hall; Marianne Harris; P Reiss; D Cooper; STEFANO VELLA; R Curry; P Robinson; J M Lange; Julio S G Montaner
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
AIDS (London, England) 2001;15(10):1269-74.
2001: Yongjun Guan; James B Whitney; Mervi Detorio; Mark A Wainberg
Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted.
Journal of virology 2001;75(9):4056-67.
2001: Matthias Götte; Masanori Kameoka; N McLellan; Luciano Cellai; Mark A Wainberg
Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription.
The Journal of biological chemistry 2001;276(9):6711-9.
2001: Yongjun Guan; James B Whitney; Chen Liang; Mark A Wainberg
Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences.
Journal of virology 2001;75(6):2776-85.
2001: Masanori Kameoka; Liwei Rong; Matthias Götte; Chen Liang; Rodney S Russell; Mark A Wainberg
Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.
Journal of virology 2001;75(6):2675-83.
2001: Michael Laughrea; N Shen; L Jetté; Jean-Luc Darlix; Lawrence Kleiman; Mark A Wainberg
Role of distal zinc finger of nucleocapsid protein in genomic RNA dimerization of human immunodeficiency virus type 1; no role for the palindrome crowning the R-U5 hairpin.
Virology 2001;281(1):109-16.
2001: Mark A Wainberg
Microbicides 2000 conference. Welcoming remarks. The global need for microbicides.
AIDS (London, England) 2001;15 Suppl 1():S1-2.
2001: Mark A Wainberg; A J White
Current insights into reverse transcriptase inhibitor-associated resistance.
Antiviral therapy 2001;6 Suppl 2():11-9.
2000: Bluma Brenner; Mark A Wainberg; Horacio Salomon; Danielle Rouleau; André Dascal; Bonnie Spira; Rafick-Pierre Sekaly; Brian Conway; Jean-Pierre Routy
Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study.
International journal of antimicrobial agents 2000;16(4):429-34.
2000: N Richard; Horacio Salomon; Maureen Oliveira; RF Rando; TS Mansour; Z Gu; Mark A Wainberg
Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.
Antiviral chemistry & chemotherapy 2000;11(6):359-65.
2000: Bluma G Brenner; Mark A Wainberg
The role of antiretrovirals and drug resistance in vertical transmission of HIV-1 infection.
Annals of the New York Academy of Sciences 2000;918():9-15.
2000: Shan Cen; Ahmad Khorchid; Juliana Gabor; Liwei Rong; Mark A Wainberg; Lawrence Kleiman
Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1.
Journal of virology 2000;74(22):10796-800.
2000: Yongjun Guan; James B Whitney; Karidia Diallo; Mark A Wainberg
Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus.
Journal of virology 2000;74(19):8854-60.
2000: Xin Wei; Matthias Götte; Mark A Wainberg
Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers.
Nucleic acids research 2000;28(16):3065-74.
2000: Chen Liang; Liwei Rong; Rodney S Russell; Mark A Wainberg
Deletion mutagenesis downstream of the 5' long terminal repeat of human immunodeficiency virus type 1 is compensated for by point mutations in both the U5 region and gag gene.
Journal of virology 2000;74(14):6251-61.
2000: N Shen; L Jetté; Chen Liang; Mark A Wainberg; Michael Laughrea
Impact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging.
Journal of virology 2000;74(12):5729-35.
2000: Ahmad Khorchid; Hassan Javanbakht; S Wise; Rabih Halwani; Michael A Parniak; Mark A Wainberg; Lawrence Kleiman
Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.
Journal of molecular biology 2000;299(1):17-26.
2000: N Richard; Horacio Salomon; RF Rando; TS Mansour; Terry Bowlin; Mark A Wainberg
Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.
Antimicrobial agents and chemotherapy 2000;44(5):1127-31.
2000: M Hsu; Liwei Rong; Hugues de Rocquigny; Bernard P Roques; Mark A Wainberg
The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions.
Nucleic acids research 2000;28(8):1724-9.
2000: Matthias Götte; Dominique Arion; Michael A Parniak; Mark A Wainberg
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
Journal of virology 2000;74(8):3579-85.
2000: Horacio Salomon; Mark A Wainberg; Bluma Brenner; Yudong Quan; Danielle Rouleau; Pierre Coté; Richard LeBlanc; Eric A Lefebvre; Bonnie Spira; Christos M Tsoukas; Rafick-Pierre Sekaly; Brian Conway; DL Mayers; Jean-Pierre Routy
Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
AIDS (London, England) 2000;14(2):F17-23.
2000: M Hsu; Mark A Wainberg
Interactions between human immunodeficiency virus type 1 reverse transcriptase, tRNA primer, and nucleocapsid protein during reverse transcription.
Journal of human virology 2000;3(1):16-26.
1999: Z Gu; Mark A Wainberg; Nghe Nguyen-Ba; Lucille L'Heureux; JM de Muys; Terry Bowlin; RF Rando
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
Antimicrobial agents and chemotherapy 1999;43(10):2376-82.
1999: C DeLuca; H Kwon; Rongtuan Lin; Mark A Wainberg; John Hiscott
NF-kappaB activation and HIV-1 induced apoptosis.
Cytokine & growth factor reviews 1999;10(3-4):235-53.
1999: P Génin; Yaël Mamane; H Kwon; Cecile Le Page; Mark A Wainberg; John Hiscott
Differential regulation of CC chemokine gene expression in human immunodeficiency virus-infected myeloid cells.
Virology 1999;261(2):205-15.
1999: JM de Muys; Henriette Gourdeau; Nghe Nguyen-Ba; DL Taylor; Parvin Ahmed; TS Mansour; C Locas; N Richard; Mark A Wainberg; RF Rando
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
Antimicrobial agents and chemotherapy 1999;43(8):1835-44.
1999: Chen Liang; Liwei Rong; Yudong Quan; Michael Laughrea; Lawrence Kleiman; Mark A Wainberg
Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.
Journal of virology 1999;73(8):7014-20.
1999: Yudong Quan; Liwei Rong; Chen Liang; Mark A Wainberg
Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1.
Journal of virology 1999;73(8):6700-7.
1999: Mark A Wainberg; L O Kallings
The International Conference on AIDS. Why we chose South Africa.
AIDS (London, England) 1999;13(11):11-2.
1999: Chen Liang; Liwei Rong; E Cherry; Lawrence Kleiman; Michael Laughrea; Mark A Wainberg
Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins.
Journal of virology 1999;73(7):6147-51.
1999: Mark A Wainberg
A new source of resistance to HIV drugs.
JAMA : the journal of the American Medical Association 1999;281(23):2169-70.
1999: Ralph J Germinario; Susan P Colby-Germinario; Andrea Acel; R Chandok; K Davison; Johnson Mak; Lawrence Kleiman; E Faust; Mark A Wainberg
Effect of insulin-like growth factor I on HIV type 1 long terminal repeat-driven chloramphenicol acetyltransferase expression.
AIDS research and human retroviruses 1999;15(9):829-36.
1999: Matthias Götte; X Li; Mark A Wainberg
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction.
Archives of biochemistry and biophysics 1999;365(2):199-210.
1999: Shan Cen; Yue Huang; Ahmad Khorchid; Jean-Luc Darlix; Mark A Wainberg; Lawrence Kleiman
The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA.
Journal of virology 1999;73(5):4485-8.
1999: Matthias Götte; G Maier; AM Onori; Luciano Cellai; Mark A Wainberg; Hermann Heumann
Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal.
The Journal of biological chemistry 1999;274(16):11159-69.
1999: J Machado; Horacio Salomon; Maureen Oliveira; Christos M Tsoukas; A A Krayevsky; Mark A Wainberg
Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT.
Nucleosides & nucleotides 1999;18(4-5):901-6.
1999: Z Gu; Mark A Wainberg; P Nguyen-Ba; Lucille L'Heureux; JM de Muys; RF Rando
Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.
Nucleosides & nucleotides 1999;18(4-5):891-2.
1999: N Richard; Horacio Salomon; Maureen Oliveira; RF Rando; Mark A Wainberg
Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.
Nucleosides & nucleotides 1999;18(4-5):773-8.
1999: M Hsu; E Cherry; Yudong Quan; N Richard; Lawrence Kleiman; Mark A Wainberg
Effect of mutations in NC7 on endogenous reverse transcription in HIV-1.
Leukemia 1999;13 Suppl 1():S113-5.
1999: Mark A Wainberg
The need for microbicides: why aren't women's groups more involved in the fight against AIDS?
AIDS research and human retroviruses 1999;15(5):405-6.
1999: Gadi Borkow; Dominique Arion; Mark A Wainberg; Michael A Parniak
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 1999;43(2):259-63.
1999: Michael Laughrea; N Shen; L Jetté; Mark A Wainberg
Variant effects of non-native kissing-loop hairpin palindromes on HIV replication and HIV RNA dimerization: role of stem-loop B in HIV replication and HIV RNA dimerization.
Biochemistry 1999;38(1):226-34.
1999: N Richar; Yudong Quan; Horacio Salomon; M Hsu; J Bedard; P Richard Harrigan; RF Rando; TS Mansour; Terry Bowlin; Mark A Wainberg
Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC).
Antiviral therapy 1999;4(3):171-7.
1999: Yudong Quan; Dimitrios Motakis; Robert W Buckheit; Z Q Xu; M T Flavin; Michael A Parniak; Mark A Wainberg
Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Antiviral therapy 1999;4(4):203-9.
1999: Mark A Wainberg; Michael D Miller; Yudong Quan; Horacio Salomon; Andrew S Mulato; PD Lamy; Nicolas A Margot; KE Anton; Julie M Cherrington
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Antiviral therapy 1999;4(2):87-94.
1999: Bluma G Brenner; Mark A Wainberg
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection.
Infectious diseases in obstetrics and gynecology 1999;7(1-2):80-90.
1998: Yudong Quan; Chen Liang; P Inouye; Mark A Wainberg
Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products.
Nucleic acids research 1998;26(24):5692-8.
1998: E Cherry; Chen Liang; Liwei Rong; Yudong Quan; P Inouye; Xiaodong Li; N Morin; M Kotler; Mark A Wainberg
Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.
Journal of molecular biology 1998;284(1):43-56.
1998: Sandra Rae; Janet Raboud; Brian Conway; P Reiss; STEFANO VELLA; D Cooper; J Lange; Marianne Harris; Mark A Wainberg; P Robinson; M Myers; D Hall; Julio S G Montaner
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
AIDS (London, England) 1998;12(16):2185-92.
1998: Liwei Rong; Chen Liang; M Hsu; Lawrence Kleiman; P Petitjean; Hugues de Rocquigny; Bernard P Roques; Mark A Wainberg
Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA.
Journal of virology 1998;72(11):9353-8.
1998: Janet Raboud; Julio S G Montaner; Brian Conway; Sandra Rae; P Reiss; STEFANO VELLA; D Cooper; J Lange; Marianne Harris; Mark A Wainberg; P Robinson; M Myers; D Hall
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
AIDS (London, England) 1998;12(13):1619-24.
1998: C Caro; Susan P Colby-Germinario; B Brenner; M Oliveira; Mark A Wainberg; Ralph J Germinario
Sugar transport and glut transporter expression in a variety of human immunodeficiency virus-1 (HIV-1) chronically infected target cell lines.
The international journal of biochemistry & cell biology 1998;30(9):1031-8.
1998: Yudong Quan; P Inouye; Chen Liang; Liwei Rong; Matthias Götte; Mark A Wainberg
Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing.
The Journal of biological chemistry 1998;273(34):21918-25.
1998: Chen Liang; Liwei Rong; Matthias Götte; Xiaodong Li; Yudong Quan; Lawrence Kleiman; Mark A Wainberg
Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription.
The Journal of biological chemistry 1998;273(33):21309-15.
1998: William C. Drosopoulos; Lisa F Rezende; Mark A Wainberg; Vinayaka R Prasad
Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus?
Journal of molecular medicine (Berlin, Germany) 1998;76(9):604-12.
1998: Chen Liang; Liwei Rong; Michael Laughrea; Lawrence Kleiman; Mark A Wainberg
Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication.
Journal of virology 1998;72(8):6629-36.
1998: Mark A Wainberg; G Friedland
Public health implications of antiretroviral therapy and HIV drug resistance.
JAMA : the journal of the American Medical Association 1998;279(24):1977-83.
1998: E Cherry; N Morin; Mark A Wainberg
Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
AIDS (London, England) 1998;12(9):967-75.
1998: P Inouye; E Cherry; M Hsu; Susan Zolla-Pazner; Mark A Wainberg
Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
AIDS research and human retroviruses 1998;14(9):735-40.
1998: DL Mayers; J Bethel; Mark A Wainberg; O Weislow; SM Schnittman
Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
The Journal of infectious diseases 1998;177(6):1730-3.
1998: Yue Huang; Ahmad Khorchid; Juliana Gabor; J Wang; X Li; Jean-Luc Darlix; Mark A Wainberg; Lawrence Kleiman
The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1.
Journal of virology 1998;72(5):3907-15.
1998: C DeLuca; H Kwon; Nadine Pelletier; Mark A Wainberg; John Hiscott
NF-kappaB protects HIV-1-infected myeloid cells from apoptosis.
Virology 1998;244(1):27-38.
1998: Christos M Tsoukas; J Raboud; Nicole F Bernard; Julio S G Montaner; M J Gill; A Rachlis; Ignatius W Fong; Walter F Schlech; O Djurdjev; J Freedman; R Thomas; R Lafrenière; Mark A Wainberg; S Cassol; Michael O'Shaughnessy; J Todd; F Volvovitz; G E Smith
Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
AIDS research and human retroviruses 1998;14(6):483-90.
1998: H Kwon; Nadine Pelletier; C DeLuca; Pierre Genin; S Cisternas; Rongtuan Lin; Mark A Wainberg; John Hiscott
Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells.
The Journal of biological chemistry 1998;273(13):7431-40.
1998: Yudong Quan; Z Gu; Xiaodong Li; Chen Liang; Michael A Parniak; Mark A Wainberg
Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
Journal of molecular biology 1998;277(2):237-47.
1998: N Morin; E Cherry; Xiaodong Li; Mark A Wainberg
Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication.
Journal of human virology 1998;1(3):240-7.
1998: Andrea Acel; B E Udashkin; Mark A Wainberg; E A Faust
Efficient gap repair catalyzed in vitro by an intrinsic DNA polymerase activity of human immunodeficiency virus type 1 integrase.
Journal of virology 1998;72(3):2062-71.
1998: Mark A Wainberg; William Cameron
HIV resistance to antiviral drugs: public health implications.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 1998;1(2):104-8.
1998: Horacio Salomon; Julio S G Montaner; A Belmonte; Mark A Wainberg
Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase.
Antiviral therapy 1998;3(3):177-82.
1997: E Cherry; M Slater; Horacio Salomon; Erling Rud; Mark A Wainberg
Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Antimicrobial agents and chemotherapy 1997;41(12):2763-5.
1997: Chen Liang; Liwei Rong; N Morin; E Cherry; Yue Huang; Lawrence Kleiman; Mark A Wainberg
The roles of the human immunodeficiency virus type 1 Pol protein and the primer binding site in the placement of primer tRNA(3Lys) onto viral genomic RNA.
Journal of virology 1997;71(12):9075-86.
1997: M Hsu; P Inouye; Lisa F Rezende; N Richard; Z Li; Vinayaka R Prasad; Mark A Wainberg
Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.
Nucleic acids research 1997;25(22):4532-6.
1997: Stephan Bour; R Geleziunas; Mark A Wainberg
Inhibition of CD4 translation mediated by human immunodeficiency virus type 1 envelope protein in a cell-free system.
The Journal of biological chemistry 1997;272(46):29005-14.
1997: Chen Liang; Xiaodong Li; Yudong Quan; Michael Laughrea; Lawrence Kleiman; John Hiscott; Mark A Wainberg
Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription.
Journal of molecular biology 1997;272(2):167-77.
1997: Xiaodong Li; Chen Liang; Yudong Quan; R Chandok; Michael Laughrea; Michael A Parniak; Lawrence Kleiman; Mark A Wainberg
Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.
Journal of virology 1997;71(8):6003-10.
1997: Chen Liang; Xiaodong Li; Liwei Rong; P Inouye; Yudong Quan; Lawrence Kleiman; Mark A Wainberg
The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity.
Journal of virology 1997;71(8):5750-7.
1997: Yue Huang; Ahmad Khorchid; J Wang; Michael A Parniak; Jean-Luc Darlix; Mark A Wainberg; Lawrence Kleiman
Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1.
Journal of virology 1997;71(6):4378-84.
1997: X Li; Y Quan; Mark A Wainberg
Controlling elements in replication of the human immunodeficiency virus type 1.
Cellular and molecular biology (Noisy-le-Grand, France) 1997;43(3):443-54.
1997: Michael Laughrea; L Jetté; Johnson Mak; Lawrence Kleiman; Chen Liang; Mark A Wainberg
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization.
Journal of virology 1997;71(5):3397-406.
1997: Mark A Wainberg
Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials.
Leukemia 1997;11 Suppl 3():85-8.
1997: Gadi Borkow; J Barnard; T M Nguyen; A Belmonte; Mark A Wainberg; Michael A Parniak
Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
Journal of virology 1997;71(4):3023-30.
1997: K Nagai; Andrew Hoi-Tao Wong; Suiyang Li; W N Tam; Andrew R Cuddihy; Nahum Sonenberg; M B Mathews; John Hiscott; Mark A Wainberg; Antonis E Koromilas
Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR.
Journal of virology 1997;71(2):1718-25.
1997: Johnson Mak; Ahmad Khorchid; Q Cao; Yue Huang; I Lowy; Michael A Parniak; Vinayaka R Prasad; Mark A Wainberg; Lawrence Kleiman
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1.
Journal of molecular biology 1997;265(4):419-31.
1997: Y Huang; J Wang; A Shalom; Z Li; Ahmad Khorchid; Mark A Wainberg; Lawrence Kleiman
Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1.
Journal of virology 1997;71(1):726-8.
1996: Mark A Wainberg; M Hsu; Z Gu; Gadi Borkow; M A Parniak
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
AIDS (London, England) 1996;10 Suppl 5():S3-10.
1996: Z Li; A Shalom; Yue Huang; Johnson Mak; E Arts; Mark A Wainberg; Lawrence Kleiman
Multiple forms of tRNA(Lys3) in HIV-1.
Biochemical and biophysical research communications 1996;227(2):530-40.
1996: A Foli; K M Sogocio; B Anderson; Mark F Kavlick; MW Saville; Mark A Wainberg; Z Gu; Julie M Cherrington; Hiroaki Mitsuya; Robert Yarchoan
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Antiviral research 1996;32(2):91-8.
1996: Eric J Arts; S R Stetor; X Li; Jason W Rausch; Kathryn Howard; B Ehresmann; T W North; Birgitta M Wöhrl; Roger S Goody; Mark A Wainberg; S F Grice
Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(19):10063-8.
1996: P Beauparlant; H Kwon; M Clarke; Rongtuan Lin; Nahum Sonenberg; Mark A Wainberg; John Hiscott
Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
Journal of virology 1996;70(9):5777-85.
1996: Dominique Arion; R Harada; X Li; Mark A Wainberg; M A Parniak
HIV-1 reverse transcriptase shows no specificity for the binding of primer tRNA(Lys3).
Biochemical and biophysical research communications 1996;225(3):839-43.
1996: Dominique Arion; Gadi Borkow; Z Gu; Mark A Wainberg; M A Parniak
The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase.
The Journal of biological chemistry 1996;271(33):19860-4.
1996: Yudong Quan; Z Gu; Xiaodong Li; Z Li; C D Morrow; Mark A Wainberg
Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1.
Journal of virology 1996;70(8):5642-5.
1996: C DeLuca; A Roulston; Antonis E Koromilas; Mark A Wainberg; John Hiscott
Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradation.
Journal of virology 1996;70(8):5183-93.
1996: Xiaodong Li; Yudong Quan; E J Arts; Z Li; B D Preston; Hugues de Rocquigny; Bernard P Roques; Jean-Luc Darlix; Lawrence Kleiman; M A Parniak; Mark A Wainberg
Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.
Journal of virology 1996;70(8):4996-5004.
1996: Y Kew; Horacio Salomon; L R Olsen; Mark A Wainberg; Vinayaka R Prasad
The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.
Antimicrobial agents and chemotherapy 1996;40(7):1711-4.
1996: Yue Huang; A Shalom; Z Li; J Wang; Johnson Mak; Mark A Wainberg; Lawrence Kleiman
Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription.
Journal of virology 1996;70(7):4700-6.
1996: Mark A Wainberg; L Lewis; Horacio Salomon; Z Gu; A Keller; N Cammack; J Goldsmith; J Church; B Spira; S Wheeler; P Pizzo
Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients.
Antiviral therapy 1996;1(2):98-104.
1996: Z Gu; Xiaodong Li; Yudong Quan; M A Parniak; Mark A Wainberg
Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
Journal of virology 1996;70(4):2620-6.
1996: L Mercure; G S Tannenbaum; Hyman M Schipper; D Phaneuf; Mark A Wainberg
Expression of the somatostatin gene in human astrocytoma cell lines.
Clinical and diagnostic laboratory immunology 1996;3(2):151-5.
1996: E J Arts; Mark A Wainberg
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.
Antimicrobial agents and chemotherapy 1996;40(3):527-40.
1996: Mark A Wainberg; William C. Drosopoulos; Horacio Salomon; M Hsu; Gadi Borkow; M Parniak; Z Gu; Q Song; J Manne; S Islam; G Castriota; Vinayaka R Prasad
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Science (New York, N.Y.) 1996;271(5253):1282-5.
1996: R S Fletcher; G Holleschak; E Nagy; Dominique Arion; Gadi Borkow; Z Gu; Mark A Wainberg; M A Parniak
Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.
Protein expression and purification 1996;7(1):27-32.
1996: Eric J Arts; J P Marois; Z Gu; Stuart F J Le Grice; Mark A Wainberg
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Journal of virology 1996;70(2):712-20.
1996: E J Arts; Mark A Wainberg
Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription.
Advances in virus research 1996;46():97-163.
1995: Z Gu; Yudong Quan; Z Li; E J Arts; Mark A Wainberg
Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
The Journal of biological chemistry 1995;270(52):31046-51.
1995: J S Montaner; Martin T Schechter; Anita Rachlis; J Gill; R Beaulieu; Christos M Tsoukas; Janet Raboud; B Cameron; Horacio Salomon; LM Dunkle; L Smaldone; Mark A Wainberg
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Annals of internal medicine 1995;123(8):561-71.
1995: Horacio Salomon; Sandra Pampuro; Z Gu; J S Montaner; O Libonatti; Mark A Wainberg
[Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
Revista Argentina de microbiología 1995;27(4):214-29.
1995: Z Gu; Q Gao; E A Faust; Mark A Wainberg
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
The Journal of general virology 1995;76 ( Pt 10)():2601-5.
1995: A Roulston; Rongtuan Lin; P Beauparlant; Mark A Wainberg; John Hiscott
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors.
Microbiological reviews 1995;59(3):481-505.
1995: R S Fletcher; Dominique Arion; Gadi Borkow; Mark A Wainberg; G I Dmitrienko; M A Parniak
Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.
Biochemistry 1995;34(32):10106-12.
1995: Z Gu; Horacio Salomon; Julie M Cherrington; Andrew S Mulato; MS Chen; Robert Yarchoan; A Foli; K M Sogocio; Mark A Wainberg
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
Antimicrobial agents and chemotherapy 1995;39(8):1888-91.
1995: E A Faust; Andrea Acel; B Udashkin; Mark A Wainberg
Human immunodeficiency virus type 1 integrase stabilizes a linearized HIV-1 LTR plasmid in vivo.
Biochemistry and molecular biology international 1995;36(4):745-58.
1995: Mark A Wainberg; Z Gu
Targeting HIV reverse transcriptase in novel ways.
Nature medicine 1995;1(7):628-9.
1995: Ralph J Germinario; T DeSantis; Mark A Wainberg
Insulin-like growth factor 1 and insulin inhibit HIV type 1 replication in cultured cells.
AIDS research and human retroviruses 1995;11(5):555-61.
1995: Mark A Wainberg; Horacio Salomon; Z Gu; J S Montaner; T P Cooley; R McCaffrey; J Ruedy; H M Hirst; N Cammack; J Cameron
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
AIDS (London, England) 1995;9(4):351-7.
1995: Z Gu; E J Arts; M A Parniak; Mark A Wainberg
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(7):2760-4.
1995: Stephan Bour; R Geleziunas; Mark A Wainberg
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.
Microbiological reviews 1995;59(1):63-93.
1995: L Mercure; D Phaneuf; Mark A Wainberg
Differential effect of the immunomodulatory hormone somatostatin on replication of human immunodeficiency virus type 1 in CD4+ and CD8+ T lymphocytes.
Clinical and diagnostic laboratory immunology 1995;2(2):192-8.
1995: Mark A Wainberg; Z Gu; Horacio Salomon; E J Arts; Lawrence Kleiman; M A Parniak; N Morin
[Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds].
Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie 1995;318(3):315-28.
1995: TS Mansour; H Jin; W Wang; E U Hooker; C Ashman; N Cammack; Horacio Salomon; A R Belmonte; Mark A Wainberg
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro.
Journal of medicinal chemistry 1995;38(1):1-4.
1994: Yue Huang; Johnson Mak; Q Cao; Z Li; Mark A Wainberg; Lawrence Kleiman
Incorporation of excess wild-type and mutant tRNA(3Lys) into human immunodeficiency virus type 1.
Journal of virology 1994;68(12):7676-83.
1994: Z Gu; R S Fletcher; E J Arts; Mark A Wainberg; M A Parniak
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
The Journal of biological chemistry 1994;269(45):28118-22.
1994: Xiaodong Li; Johnson Mak; E J Arts; Z Gu; Lawrence Kleiman; Mark A Wainberg; M A Parniak
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication.
Journal of virology 1994;68(10):6198-206.
1994: Bluma G Brenner; M Gornitsky; Mark A Wainberg
Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.
Clinical and diagnostic laboratory immunology 1994;1(5):538-44.
1994: Stephan Bour; R Geleziunas; Mark A Wainberg
The role of CD4 and its downmodulation in establishment and maintenance of HIV-1 infection.
Immunological reviews 1994;140():147-71.
1994: Horacio Salomon; A Belmonte; K Nguyen; Z Gu; M Gelfand; Mark A Wainberg
Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
Journal of clinical microbiology 1994;32(8):2000-2.
1994: L Mercure; R Lalonde; D Phaneuf; B Brenner; Mark A Wainberg
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.
Clinical and diagnostic laboratory immunology 1994;1(4):482-5.
1994: E J Arts; Johnson Mak; Lawrence Kleiman; Mark A Wainberg
DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity.
The Journal of general virology 1994;75 ( Pt 7)():1605-13.
1994: R Geleziunas; Stephan Bour; Mark A Wainberg
Cell surface down-modulation of CD4 after infection by HIV-1.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1994;8(9):593-600.
1994: Marilyn S Smith; Horacio Salomon; Mark A Wainberg
Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.
Clinical and investigative medicine. Médecine clinique et experimentale 1994;17(3):226-43.
1994: E J Arts; Xiaodong Li; Z Gu; Lawrence Kleiman; M A Parniak; Mark A Wainberg
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.
The Journal of biological chemistry 1994;269(20):14672-80.
1994: R Geleziunas; Stephan Bour; Mark A Wainberg
HIV-1 associated down-modulation of CD4 gene expression is differentially restricted in lymphocytic and monocytic cell lines.
Journal of leukocyte biology 1994;55(5):589-95.
1994: L Mercure; B J Brenner; D Phaneuf; Christos M Tsoukas; Mark A Wainberg
Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.
Antimicrobial agents and chemotherapy 1994;38(5):986-90.
1994: E J Arts; Mark A Wainberg
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription.
Antimicrobial agents and chemotherapy 1994;38(5):1008-16.
1994: Bluma G Brenner; C Vo; Mark A Wainberg
Different effects of breast cancer, HIV-1 infection and chemotherapy on inducible natural immunity.
Leukemia 1994;8 Suppl 1():S183-5.
1994: A Roulston; L Conti; V McKiel; Mark A Wainberg; John Hiscott
Virus induction of NF-kappa B/Rel proteins and type I interferon gene expression in myelomonoblastic cells.
Leukemia 1994;8 Suppl 1():S170-4.
1994: R Geleziunas; Stephan Bour; Mark A Wainberg
Correlation between high level gp160 expression and reduced CD4 biosynthesis in clonal derivatives of human immunodeficiency virus type 1-infected U-937 cells.
The Journal of general virology 1994;75 ( Pt 4)():857-65.
1994: E J Arts; Johnson Mak; Lawrence Kleiman; Mark A Wainberg
Mature reverse transcriptase (p66/p51) is responsible for low levels of viral DNA found in human immunodeficiency virus type 1 (HIV-1).
Leukemia 1994;8 Suppl 1():S175-8.
1994: Z Gu; Q Gao; H Fang; M A Parniak; Bluma G Brenner; Mark A Wainberg
Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.
Leukemia 1994;8 Suppl 1():S166-9.
1994: Johnson Mak; M Jiang; Mark A Wainberg; Marie-Louise Hammarskjöld; David Rekosh; Lawrence Kleiman
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles.
Journal of virology 1994;68(4):2065-72.
1994: L Mercure; Mark A Wainberg
Direct involvement of extracellular HIV-1 virions in the apoptosis of CD8+ lymphocytes: a two-step model.
Medical hypotheses 1994;42(3):159-68.
1994: M Tremblay; S Meloche; S Gratton; Mark A Wainberg; Rafick-Pierre Sékaly
Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression.
The EMBO journal 1994;13(4):774-83.
1994: Z Gu; Q Gao; H Fang; Horacio Salomon; M A Parniak; E Goldberg; J Cameron; Mark A Wainberg
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Antimicrobial agents and chemotherapy 1994;38(2):275-81.
1994: Q Gao; Z Gu; Horacio Salomon; K Nagai; M A Parniak; Mark A Wainberg
Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
Archives of virology 1994;136(1-2):111-22.
1994: R Geleziunas; Stephan Bour; Mark A Wainberg
Human immunodeficiency virus type 1-associated CD4 downmodulation.
Advances in virus research 1994;44():203-66.
1993: L Mercure; D Phaneuf; Mark A Wainberg
Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells.
The Journal of general virology 1993;74 ( Pt 10)():2077-83.
1993: S St Luce; E Arts; R Geleziunas; Stephan Bour; Mark A Wainberg
Infection of human monocyte-derived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission.
Journal of medical virology 1993;41(1):71-8.
1993: X Li; Z Gu; R Geleziunas; Lawrence Kleiman; Mark A Wainberg; M A Parniak
Expression, purification, and RNA-binding properties of HIV-1 p15gag nucleocapsid protein.
Protein expression and purification 1993;4(4):304-11.
1993: Bluma G Brenner; C Gryllis; M Gornitsky; Mark A Wainberg
Changes in natural immunity during the course of HIV-1 infection.
Clinical and experimental immunology 1993;93(2):142-8.
1993: Q Gao; Z Gu; M A Parniak; J Cameron; N Cammack; C Boucher; Mark A Wainberg
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Antimicrobial agents and chemotherapy 1993;37(6):1390-2.
1993: R Geleziunas; E J Arts; F Boulerice; H Goldman; Mark A Wainberg
Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
Antimicrobial agents and chemotherapy 1993;37(6):1305-12.
1993: H Soudeyns; R Geleziunas; G Shyamala; John Hiscott; Mark A Wainberg
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1.
Virology 1993;194(2):758-68.
1993: J Wu; E Amandoron; X Li; Mark A Wainberg; M A Parniak
Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain.
The Journal of biological chemistry 1993;268(14):9980-5.
1993: Mark A Wainberg; R Beaulieu; Christos M Tsoukas; R Thomas
Detection of zidovudine-resistant variants of HIV-1 in genital fluids.
AIDS (London, England) 1993;7(3):433-4.
1993: X Li; E Amandoron; Mark A Wainberg; M A Parniak
Generation and characterization of murine monoclonal antibodies reactive against N-terminal and other regions of HIV-1 reverse transcriptase.
Journal of medical virology 1993;39(3):251-9.
1993: Mark A Wainberg; Horacio Salomon; B Spira; L Mercure; J Wainberg; K Nagai; Z Bentwich; J Montaner
HIV resistance to anti-viral drugs.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 1993;26(3):299-308.
1993: Mark A Wainberg; R Geleziunas; Stephan Bour
The role and fate of the CD4 molecule in lymphocytes and monocytes infected by HIV-1.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 1993;26(2):123-36.
1993: Q Gao; Z Gu; J Hiscott; G Dionne; Mark A Wainberg
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Antimicrobial agents and chemotherapy 1993;37(1):130-3.
1993: Mark A Wainberg; Z Gu; Q Gao; E Arts; R Geleziunas; Stephan Bour; R Beaulieu; Christos M Tsoukas; J Singer; J Montaner
Clinical correlates and molecular basis of HIV drug resistance.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S36-46.
1992: Z Gu; Q Gao; X Li; M A Parniak; Mark A Wainberg
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Journal of virology 1992;66(12):7128-35.
1992: C Gryllis; Mark A Wainberg; Z Bentwich; M Gornitsky; Bluma G Brenner
Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals.
Clinical and experimental immunology 1992;89(3):356-61.
1992: Mark A Wainberg; Stephan Bour; R Geleziunas; Z Bentwich
[Antiviral strategies in the replication of human immunodeficiency virus].
L'unión médicale du Canada 1992;121(5):307-9, 312-4.
1992: M Jiang; Johnson Mak; Mark A Wainberg; M A Parniak; E Cohen; Lawrence Kleiman
Variable tRNA content in HIV-1IIIB.
Biochemical and biophysical research communications 1992;185(3):1005-15.
1992: A Roulston; M D'Addario; F Boulerice; S Caplan; Mark A Wainberg; John Hiscott
Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells.
The Journal of experimental medicine 1992;175(3):751-63.
1992: X J Yao; Mark A Wainberg; M A Parniak
Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris.
Virology 1992;187(1):56-62.
1992: M D'Addario; Mark A Wainberg; John Hiscott
Activation of cytokine genes in HIV-1 infected myelomonoblastic cells by phorbol ester and tumor necrosis factor.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(4):1222-9.
1992: F Boulerice; R Geleziunas; Stephan Bour; H L Li; M D'Addario; A Roulston; John Hiscott; Mark A Wainberg
Differential susceptibilities of U-937 cell clones to infection by human immunodeficiency virus type 1.
Journal of virology 1992;66(2):1183-7.
1992: Q Gao; Z X Gu; M A Parniak; X G Li; Mark A Wainberg
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
Journal of virology 1992;66(1):12-9.
1992: Q Gao; M A Parniak; Z Gu; Mark A Wainberg
Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.
Leukemia 1992;6 Suppl 3():192S-195S.
1992: Mark A Wainberg; M Tremblay; R Rooke; M Fanning; Christos M Tsoukas; J S Montaner; Michael O'Shaughnessy; J Ruedy
Characterization of zidovudine resistant variants of HIV-1 isolated from patients on prolonged therapy.
Drugs under experimental and clinical research 1992;18(7):283-90.
1991: Stephan Bour; F Boulerice; Mark A Wainberg
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1.
Journal of virology 1991;65(12):6387-96.
1991: Bluma G Brenner; C Gryllis; Mark A Wainberg
Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases.
Journal of leukocyte biology 1991;50(6):628-40.
1991: X J Yao; Mark A Wainberg; M Richard; M Pollak
The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin.
Antimicrobial agents and chemotherapy 1991;35(12):2636-8.
1991: X J Yao; Mark A Wainberg; M Pollak
The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin.
AIDS (London, England) 1991;5(11):1389-91.
1991: F Boulerice; X G Li; A Lvovich; Mark A Wainberg
Recovery of infectious human immunodeficiency virus type 1 after fusion of defectively infected clones of U-937 cells.
Journal of virology 1991;65(10):5589-92.
1991: H Soudeyns; X I Yao; Q Gao; B Belleau; J L Kraus; N Nguyen-Ba; B Spira; Mark A Wainberg
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.
Antimicrobial agents and chemotherapy 1991;35(7):1386-90.
1991: R Rooke; M A Parniak; M Tremblay; H Soudeyns; X G Li; Q Gao; X J Yao; Mark A Wainberg
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
Antimicrobial agents and chemotherapy 1991;35(5):988-91.
1991: R Geleziunas; A McQuillan; Areti Malapetsa; M Hutchinson; D Kopriva; Mark A Wainberg; John Hiscott; J Bramson; Lawrence Panasci
Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards.
Journal of the National Cancer Institute 1991;83(8):557-64.
1991: Bluma G Brenner; C Gryllis; M Gornitsky; W Cupples; Mark A Wainberg
Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations.
Anticancer research 1991;11(2):969-74.
1991: Lawrence Kleiman; S Caudry; F Boulerice; Mark A Wainberg; M A Parniak
Incorporation of tRNA into normal and mutant HIV-1.
Biochemical and biophysical research communications 1991;174(3):1272-80.
1991: R Geleziunas; Stephan Bour; F Boulerice; John Hiscott; Mark A Wainberg
Diminution of CD4 surface protein but not CD4 messenger RNA levels in monocytic cells infected by HIV-1.
AIDS (London, England) 1991;5(1):29-33.
1990: M D'Addario; A Roulston; Mark A Wainberg; John Hiscott
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells.
Journal of virology 1990;64(12):6080-9.
1990: C Gryllis; Mark A Wainberg; M Gornitsky; B Brenner
Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.
AIDS (London, England) 1990;4(12):1205-12.
1990: M Dubreuil; L Sportza; M D'Addario; J Lacoste; R Rooke; Mark A Wainberg; John Hiscott
Inhibition of HIV-1 transmission by interferon and 3'-azido-3'-deoxythymidine during de novo infection of promonocytic cells.
Virology 1990;179(1):388-94.
1990: M Tremblay; K Numazaki; X G Li; M Gornitsky; John Hiscott; Mark A Wainberg
Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(9):2896-901.
1990: J Lacoste; M D'Addario; A Roulston; Mark A Wainberg; John Hiscott
Cell-specific differences in activation of NF-kappa B regulatory elements of human immunodeficiency virus and beta interferon promoters by tumor necrosis factor.
Journal of virology 1990;64(10):4726-34.
1990: M Tremblay; Mark A Wainberg
Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
The Journal of infectious diseases 1990;162(3):735-7.
1990: F Boulerice; Mark A Wainberg
Inhibition by AZT of HIV-1 replication in acutely infected U-937 cells.
Journal of leukocyte biology 1990;47(6):498-505.
1990: M Tremblay; S Meloche; Rafick-Pierre Sekaly; Mark A Wainberg
Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells.
The Journal of experimental medicine 1990;171(5):1791-6.
1990: F Boulerice; Stephan Bour; R Geleziunas; A Lvovich; Mark A Wainberg
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells.
Journal of virology 1990;64(4):1745-55.
1990: J S Montaner; T Le; M Fanning; Karen Gelmon; Christos M Tsoukas; J Falutz; Michael O'Shaughnessy; Mark A Wainberg; J Ruedy
The effect of zidovudine on platelet count in HIV-infected individuals.
Journal of acquired immune deficiency syndromes 1990;3(6):565-70.
1990: K Numazaki; H Goldman; T A Seemayer; I Wong; Mark A Wainberg
Infection by human cytomegalovirus and rubella virus of cultured human fetal islets of Langerhans.
In vivo (Athens, Greece) 1990;4(1):49-54.
1990: Mark A Wainberg; M Tremblay; R Rooke; N Blain; H Soudeyns; M A Parniak; X J Yao; X G Li; M Fanning; J S Montaner
Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
Annals of the New York Academy of Sciences 1990;616():346-55.
1989: M Tremblay; M Gornitsky; Mark A Wainberg
Active replication of human immunodeficiency virus type 1 by peripheral blood mononuclear cells following coincubation with herpes viruses.
Journal of medical virology 1989;29(2):109-14.
1989: Karen Gelmon; J S Montaner; M Fanning; J R Smith; J Falutz; Christos M Tsoukas; J Gill; G Wells; Michael O'Shaughnessy; Mark A Wainberg
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.
AIDS (London, England) 1989;3(9):555-61.
1989: M Tremblay; A K Sullivan; R Rooke; R Geleziunas; Christos M Tsoukas; G Shematek; N Gilmore; Mark A Wainberg
New CD4(+) cell line susceptible to infection by HIV-1.
Journal of medical virology 1989;28(4):243-9.
1989: Bluma G Brenner; A Dascal; R G Margolese; Mark A Wainberg
Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases.
Journal of leukocyte biology 1989;46(1):75-83.
1989: M Tremblay; Mark A Wainberg
Susceptibility to AZT of HIV-1 variants grown in Epstein-Barr virus-transformed B cell lines.
The Journal of infectious diseases 1989;160(1):31-6.
1989: K Numazaki; X Q Bai; H Goldman; I Wong; B Spira; Mark A Wainberg
Infection of cultured human thymic epithelial cells by human immunodeficiency virus.
Clinical immunology and immunopathology 1989;51(2):185-95.
1989: K Numazaki; H Goldman; I Wong; Mark A Wainberg
Infection of cultured human fetal pancreatic islet cells by rubella virus.
American journal of clinical pathology 1989;91(4):446-51.
1989: K Numazaki; Mark A Wainberg; J McDonald
Chlamydia trachomatis infections in infants.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1989;140(6):615-22.
1989: K Numazaki; H Goldman; I Wong; Mark A Wainberg
Maturation of human fetal and infantile thymic cells in tissue culture.
In vivo (Athens, Greece) 1989;3(2):101-7.
1989: Mark A Wainberg; J Falutz; M Fanning; J Gill; Karen Gelmon; J S Montaner; M O'Shaughnessy; Christos M Tsoukas; J Ruedy
Cessation of zidovudine therapy may lead to increased replication of HIV-1.
JAMA : the journal of the American Medical Association 1989;261(6):865-6.
1989: K Numazaki; H Goldman; I Wong; Mark A Wainberg
Replication of measles virus in cultured human thymic epithelial cells.
Journal of medical virology 1989;27(1):52-8.
1989: K Numazaki; H Goldman; X Q Bai; I Wong; Mark A Wainberg
Effects of infection by HIV-1, cytomegalovirus, and human measles virus on cultured human thymic epithelial cells.
Microbiology and immunology 1989;33(9):733-45.
1989: K Numazaki; L DeStephano; I Wong; H Goldman; B Spira; Mark A Wainberg
Replication of cytomegalovirus in human thymic epithelial cells.
Medical microbiology and immunology 1989;178(2):89-98.
1988: Mark A Wainberg; A Dascal; N Blain; L Fitz-Gibbon; F Boulerice; K Numazaki; M Tremblay
The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1.
Blood 1988;72(6):1904-10.
1988: M Tremblay; L Fitz-Gibbon; Mark A Wainberg
Heterogeneity of HIV-1 replication and antigen expression in EBV-transformed B cell lines.
Leukemia 1988;2(12 Suppl):233S-240S.
1988: V Samnotra; Ralph J Germinario; Mark A Wainberg
Presence of insulin binding sites on viral particles.
Antiviral research 1988;9(5):285-93.
1988: K Numazaki; H Goldman; I Wong; Mark A Wainberg
Viral infection of human fetal islets of Langerhans. Replication of human cytomegalovirus in cultured human fetal pancreatic islets.
American journal of clinical pathology 1988;90(1):52-7.
1988: S Roy; L Fitz-Gibbon; L Poulin; Mark A Wainberg
Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity.
Immunology 1988;64(2):233-9.
1988: Mark A Wainberg; K Numazaki; L Destephano; I Wong; H Goldman
Infection of human thymic epithelial cells by human cytomegalovirus and other viruses: effect on secretion of interleukin 1-like activity.
Clinical and experimental immunology 1988;72(3):415-21.
1988: Mark A Wainberg; O Kendall; N Gilmore
Vaccine and antiviral strategies against infections caused by human immunodeficiency virus.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1988;138(9):797-807.
1988: K Numazaki; L Destephano; H Goldman; I Wong; Mark A Wainberg
Effect of cytomegalovirus on lectin-driven mitogenesis of human thymic and peripheral blood lymphocytes.
In vivo (Athens, Greece) 1988;2(2):133-8.
1988: K Numazaki; H Goldman; Mark A Wainberg
Effect of co-incubation with cytomegalovirus on growth of interleukin 2-dependent lymphocytes.
Microbial pathogenesis 1988;4(2):137-44.
1988: S Roy; Mark A Wainberg
Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS).
Journal of leukocyte biology 1988;43(1):91-7.
1987: Mark A Wainberg; N Blain; L Fitz-Gibbon
Differential susceptibility of human lymphocyte cultures to infection by HIV.
Clinical and experimental immunology 1987;70(1):136-42.
1987: Mark A Wainberg; N Blain; B Spira
Inhibition of human lymphocyte mitogenesis by human and other retroviruses. Differential effect of interleukin-2 in restoration of responsiveness.
AIDS (London, England) 1987;1(2):83-7.
1987: L Poulin; L Grise-Miron; B Spira; Mark A Wainberg
Altered pp60src kinase activity in regressing tumors induced by Rous sarcoma virus.
Cancer letters 1987;36(1):99-110.
1987: L Poulin; B Spira; Mark A Wainberg
Studies on pp60src and associated kinase activity in regressing tumors induced by Rous sarcoma virus.
In vivo (Athens, Greece) 1987;1(2):125-30.
1987: Mark A Wainberg; J Portnoy; Christos M Tsoukas; N Gilmore
Specific stimulation of lymphocytes from patients with AIDS by herpes simplex virus antigens.
Immunology 1987;60(2):275-80.
1987: L Poulin; Mark A Wainberg
Expression of avian sarcoma virus genes in tumor cells derived from different periods of tumor growth.
Microbial pathogenesis 1987;2(2):101-12.